Tfg Asset Management Gp LTD Adaptimmune Therapeutics PLC Transaction History

Tfg Asset Management Gp LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$2.58 - $12.1 $1.94 Million - $9.08 Million	-750,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.2 - $4.52 $128,773 - $485,045	-107,311 Reduced 12.52%	750,000 $2.04 Million
Q4 2019 Feb 12, 2020	BUY	$0.72 - $1.43 $257,263 - $510,954	357,311 Added 71.46%	857,311 $1.03 Million
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $752,000 - $2.83 Million	200,000 Added 66.67%	500,000 $2.88 Million
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $2.48 Million - $4.07 Million	300,000 New	300,000 $4.07 Million

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $99.7M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Tfg Asset Management Gp LTD, based on Form 13F filings with the SEC.

Stay updated on Tfg Asset Management Gp LTD with notifications on news.